NOPARK trial reports nicotinamide riboside does not improve clinical outcomes in Parkinson disease
The authors reported that among 393 participants, the total MDS-UPDRS score increased by 2.45 points with nicotinamide riboside and decreased by 0.27 points with placebo, yielding an adjusted mean difference of 2.72 points favoring placebo. Non-motor symptom burden worsened more with nicotinamide riboside, with an adjusted mean difference of 4.22 points.
Primary source
PubMed record of a Phase III journal article, October 8, 2026
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Read the source: Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. pubmed.ncbi.nlm.nih.gov
Machine-summarized from the source above; not independently reported. How we use automation